/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

I

Ina M. Jürgenliemk‐Schulz

Utrecht University(NL)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

226

Papers

12.7K

Citations

56

h-index

128

i10-index

Ina M. Jürgenliemk‐Schulz is an academic researcher from Utrecht University. The author has contributed to research in topics: Endometrial and Cervical Cancer Treatments & Management of metastatic bone disease & Advanced Radiotherapy Techniques. The author has an h-index of 56, co-authored 193 publications.

ORCID: 0000-0003-4911-006X

Research Topics

Endometrial and Cervical Cancer Treatments Management of metastatic bone disease Advanced Radiotherapy Techniques Ovarian cancer diagnosis and treatment Cervical Cancer and HPV Research

Papers by this author

works

The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies

2018 · Clinical and Translational Radiation Oncology · 910 citations

https://doi.org/10.1016/j.ctro.2018.01.001

Richard Pötter Kari Tanderup Christian Kirisits Astrid de Leeuw

MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study

2021 · The Lancet Oncology · 583 citations

https://doi.org/10.1016/s1470-2045(20)30753-1

Richard Pötter Kari Tanderup Maximilian Schmid Ina M. Jürgenliemk‐Schulz

First patients treated with a 1.5 T MRI-Linac: clinical proof of concept of a high-precision, high-field MRI guided radiotherapy treatment

2017 · Physics in Medicine and Biology · 521 citations

https://doi.org/10.1088/1361-6560/aa9517

Bas W. Raaymakers Ina M. Jürgenliemk‐Schulz G.H. Bol M Glitzner

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

2019 · The Lancet Oncology · 438 citations

https://doi.org/10.1016/s1470-2045(19)30395-x

Stephanie M. de Boer Melanie Powell Linda Mileshkin Dionyssios Katsaros

Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer – A pooled analysis of PORTEC 1 and 2 trials

2015 · European Journal of Cancer · 412 citations

https://doi.org/10.1016/j.ejca.2015.05.015

Tjalling Bosse Elke E.M. Peters Carien L. Creutzberg Ina M. Jürgenliemk‐Schulz

PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer

2020 · International Journal of Gynecological Cancer · 235 citations

https://doi.org/10.1136/ijgc-2020-001929

Anne Sophie V M van den Heerik Nanda Horeweg Remi A. Nout Ludy Lutgens

Research topics

topics

Endometrial and Cervical Cancer Treatments

Management of metastatic bone disease

Advanced Radiotherapy Techniques

Ovarian cancer diagnosis and treatment

Cervical Cancer and HPV Research

Chat about Author

Papers

Chat

Click to start Chat